Home › Funds › ORBIMED ADVISORS LLC › RYTM

ORBIMED ADVISORS LLC position in RYTM

RHYTHM PHARMACEUTICALS INC · Health Care

ORBIMED ADVISORS LLC reported holding 322,900 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$35.9M, representing 0.72% of its reported portfolio and ranking #38 among its reported holdings. ORBIMED ADVISORS LLC has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)322.90K sh
Reported value held$35.85M
Portfolio Weight0.72%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ORBIMED ADVISORS LLC's RYTM position evolved

ORBIMED ADVISORS LLC first disclosed a stake in RYTM in Q3 2023 at 583,642 shares (US$13.4M). The position peaked in Q2 2026 at 322,900 shares, worth US$35.9M. Across 12 filings, ORBIMED ADVISORS LLC increased the stake 4 time(s), trimmed it 6 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 322,900 shares valued at US$35.9M — an increase of 8,800 shares quarter over quarter.. Notable position changes include a 31% increase in Q1 2024 (shares fell 5% over the following quarter), a 38% trim in Q3 2024 (shares rose 7% over the following quarter), a 35% trim in Q2 2025 (shares rose 60% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 583.64K $13.38M New
Q4 2023 536.64K $24.67M Reduce
Q1 2024 704.84K $30.54M Add
Q2 2024 704.84K $28.94M Hold
Q3 2024 435.90K $22.84M Reduce
Q4 2024 400.00K $22.39M Reduce
Q1 2025 380.00K $20.13M Reduce
Q2 2025 248.51K $15.70M Reduce
Q3 2025 215.15K $21.73M Reduce
Q4 2025 239.80K $25.67M Add
Q1 2026 314.10K $27.32M Add
Q2 2026 322.90K $35.85M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RYTM and 13F data

RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 52 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RYTM

All RYTM fund holders →

FAQ

How long has ORBIMED ADVISORS LLC held RYTM?

ORBIMED ADVISORS LLC has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ORBIMED ADVISORS LLC's current position in RYTM?

As of Q2 2026, ORBIMED ADVISORS LLC holds 322.90K shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $35.85M, representing 0.72% of its reported portfolio and ranking #38.

Has ORBIMED ADVISORS LLC been buying or selling RYTM?

In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC increased its position in RYTM. The position peaked in Q2 2026 at 322.90K shares.

Which other funds hold RYTM?

Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 52 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.